Nirsevimab and maternal RSVpreF vaccination show approximately 80% effectiveness against RSV-associated hospitalization in childrenNirsevimab and Maternal Vaccination Show Promise for RSV Protection

Human vaccines & immunotherapeutics Published June 26, 2026 Study authors: Oliva Isabela O, Oliveira Carlos R PubMed ↗ DOI ↗ Editorial oversight: Dr. Sofia Müller, MD · Lifespan & Whole-Person Care

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that both nirsevimab and maternal RSVpreF vaccination show approximately 80% effectiveness against RSV hospitalization.

This meta-analysis synthesizes evidence from 43 observational studies to evaluate the real-world effectiveness of nirsevimab and maternal RSVpreF vaccination in preventing RSV-associated hospitalizations among infants and young children. The analysis focuses on these two distinct immunoprophylactic strategies within a real-world setting.

The meta-analysis found that nirsevimab demonstrated 80.9% effectiveness against RSV-associated hospitalization. Similarly, maternal RSVpreF vaccination showed 79.1% effectiveness against the same outcome. These findings suggest both interventions are highly effective in reducing severe clinical outcomes associated with RSV infection.

A primary limitation noted by the authors is that all data were derived from observational studies, which may limit the ability to establish definitive causality. Clinical implementation of these strategies should be considered within the context of this real-world evidence. While the results are promising for pediatric prophylaxis, the reliance on observational data necessitates a cautious interpretation of the exact magnitude of benefit.

How this fits prior evidence

This meta-analysis extends prior coverage by providing specific effectiveness figures for nirsevimab and maternal vaccination. It builds upon a review suggesting nirsevimab may reduce RSV hospitalizations in infants by 70–90% and an ACIP recommendation for nirsevimab in infants. While a field report noted the rollout of nirsevimab without efficacy data, this meta-analysis provides specific figures: 80.9% effectiveness for nirsevimab and 79.1% for maternal RSVpreF vaccination.

Researchers looked at 43 real-world studies to see how well certain treatments protect infants and young children from respiratory syncytial virus (RSV). The study focused on two specific methods: nirsevimab and maternal RSVpreF vaccination. Both of these methods were compared against the risk of being hospitalized due to RSV.

The data showed that nirsevimab had an 80.9% effectiveness rate in preventing hospitalizations. Similarly, maternal RSVpreF vaccination showed a 79.1% effectiveness rate. These findings suggest both options could be helpful tools for protecting young children from severe illness caused by the virus.

It is important to note that these results come from observational studies rather than controlled trials. This means the data shows a link between the treatments and lower hospitalization rates, but it does not prove one causes the other. Because of this, the evidence is currently limited for making final medical decisions.

What this means for you:

Nirsevimab and maternal vaccination both show high effectiveness in reducing RSV hospitalizations in young children.

Common questions

How effective is nirsevimab against RSV?

The analysis of real-world data showed that nirsevimab had an 80.9% effectiveness rate in preventing hospitalizations associated with respiratory syncytial virus (RSV). This suggests it can be a strong option for protecting infants and young children from severe illness.

Can maternal vaccination help protect children from RSV?

Yes, the data indicates that maternal RSVpreF vaccination showed a 79.1% effectiveness rate in preventing RSV-associated hospitalizations. This suggests it may be an effective way to provide protection for infants and young children.

Is this evidence enough to change current medical practices?

The results are based on 43 observational studies rather than controlled trials. While the effectiveness rates are high, the data shows an association rather than a proven cause. You should talk to your doctor about which treatment is best for your child.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedDec 2026

PMID42348792

View Original Abstract ↓

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection and hospitalization in infants and young children worldwide. Clinical management in infants remains primarily supportive, and natural infection provides incomplete and transient immunity. For decades, prophylaxis was limited to monthly palivizumab for selected high-risk infants. Recent advances in prefusion F structural biology, antibody engineering, and maternal immunization have transformed RSV prevention. This review summarizes the biologic and clinical rationale for preventing RSV disease in pediatric populations, with emphasis on currently licensed long-acting monoclonal antibodies and maternal RSVpreF vaccination. We integrate a meta-analysis of real-world effectiveness data and discuss implementation of these novel immunoprophylactic strategies in clinical practice. Across 43 observational studies, pooled effectiveness against RSV-associated hospitalization was 80.9% for nirsevimab and 79.1% for maternal RSVpreF vaccination, demonstrating substantial real-world protection during early infancy. Success now depends on optimizing implementation and achieving equitable access.

Nirsevimab and maternal RSVpreF vaccination show approximately 80% effectiveness against RSV-associated hospitalization in childrenNirsevimab and Maternal Vaccination Show Promise for RSV Protection

How this fits prior evidence

Common questions

Study Details

High-Dose Vitamin D and Low-Dose Vitamin A May Reduce Bronchopulmonary Dysplasia in Preterm Infants

High-Dose Vitamin D May Reduce BPD in Preterm Infants

Clinical research that matters. Delivered to your inbox.

Nirsevimab and maternal RSVpreF vaccination show approximately 80% effectiveness against RSV-associated hospitalization in childrenNirsevimab and Maternal Vaccination Show Promise for RSV Protection

How this fits prior evidence

Common questions

More on Respiratory Syncytial Virus Infection

Study Details

High-Dose Vitamin D and Low-Dose Vitamin A May Reduce Bronchopulmonary Dysplasia in Preterm Infants

High-Dose Vitamin D May Reduce BPD in Preterm Infants

Clinical research that matters. Delivered to your inbox.

Related in Pediatrics

From Other Specialties